TL;DR: A 9 Nov 2026 Lancet Regional Health Europe cohort (80,000+ records) links stopping GLP-1 drugs to more CV events; it is observational, not causal.
Stopping GLP-1 Therapy and Cardiovascular Outcomes: What the 9 November 2026 Italian Cohort Study Shows
What Did the Italian GLP-1 Discontinuation Study Report?
On 9 November 2026, The Lancet Regional Health – Europe published a retrospective observational cohort study built on electronic medical records from roughly 300 Italian diabetes clinics, covering more than 80,000 people with type 2 diabetes. The work is credited to the Italian diabetologists’ association AMD, with Antonio Ceriello named as lead author in press coverage.[1][2] It compared people who stopped GLP-1 receptor agonist therapy with those who continued, and reported higher rates of cardiovascular events or death in the discontinuation group.[2][3]
Press reports put the crude figures at about four events per 100 person-years after stopping versus about two among continuers, and the headline framing in several outlets was a “doubling” of risk.[2][4] Coverage also says the association held irrespective of whether weight or blood pressure changed afterwards.[2]
Source note: we could not access the full paper when writing, so exact adjusted hazard ratios, confidence intervals and study period are not reproduced here. Figures above are as reported by secondary sources and should be checked against the journal article.
Does the Study Show That Stopping Causes the Events?
No, and the outside experts quoted in coverage were direct about it. The design shows association, not causation.[3][4] They pointed to poorer adherence, adverse effects, socioeconomic circumstances, deteriorating health and other unmeasured determinants that could drive both the decision to stop and the subsequent outcomes.[3] One commentator added that randomised evidence on what happens after discontinuation is limited.[3]
| Design question | Why it matters here |
|---|---|
| Confounding by indication | Clinical deterioration can lead to a drug being stopped and independently raise event risk. |
| Reverse causation | An emerging illness may come first; stopping is then a consequence, not a cause. |
| Immortal-time bias | How follow-up time is assigned to “stoppers” can flatter or penalise a group. |
| Unmeasured factors | Records rarely capture cost, frailty, diet, or reasons for stopping. |
Is This a New Finding?
Not entirely. A 2023 real-world analysis from Milan reported a similar pattern, with discontinuation linked to a higher risk of major cardiovascular events in people with and without a prior cardiovascular history.[3] What is new is the scale of the Italian dataset and the attention it received. In the same week, the American Heart Association’s Scientific Sessions 2026 featured a separate, preliminary comparison of GLP-1 medicines against metformin in prediabetes, a reminder that this week’s class-level headlines come from observational and abstract-stage work.[5] The FDA’s class-wide labelling action of 9 November is covered separately in our NAION label warning explainer.
The practical lesson for anyone building a literature review is that two observational papers pointing the same way are still two observational papers. Each inherits the same structural weaknesses, and agreement between them is weaker evidence than a single well-designed randomised comparison of planned continuation versus planned withdrawal.
How Should Researchers Read Observational Discontinuation Data?
Treat it as hypothesis-generating. First, check the comparison structure: were continuers and stoppers matched on baseline risk, and was follow-up aligned at a common index date? Second, check the outcome definition and whether death was counted inside a composite. Third, ask what reasons for discontinuation were recorded, if any. Fourth, separate the pharmacology question (what the receptor class does over time) from the care-pathway question (what happens to people whose treatment is interrupted). A cohort of this kind can speak, at best, to the second.
For a wider view of how label changes, trial readouts and press framing diverge, our retatrutide evidence status map sorts peer-reviewed results from sponsor-reported ones. This guide is written for laboratory researchers following the literature; individuals with questions about a prescribed medicine should speak to their prescriber.
Does This Study Involve Retatrutide?
No. The cohort concerns licensed GLP-1 receptor agonist medicines in routine diabetes care. Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist in Eli Lilly’s Phase 3 TRIUMPH and TRANSCEND programmes. It has no approved label with any regulator, and Lilly has said it plans a US submission in the first quarter of 2027.[6] Nothing in an Italian clinic-records cohort of approved drugs can be transferred to it. Our retatrutide FDA approval timeline tracks the filing milestones.
Keeping three categories separate avoids most confusion: licensed medicines under real-world surveillance, investigational drugs in sponsor trials, and research reagents with batch documentation.
Retatrutide reference material is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Ceriello A, et al. / AMD Italian diabetes clinic cohort. The Lancet Regional Health – Europe, published 9 November 2026 (journal home; full paper not accessed). thelancet.com
- LBC. Type 2 diabetes heart attack weight loss jabs. November 2026. lbc.co.uk · bdnews24.com
- Science Media Centre. Expert reaction to study on GLP-1 discontinuation and cardiovascular outcomes. November 2026. sciencemediacentre.org
- The Pharmaceutical Journal. Stopping GLP-1s linked to twice the risk of heart attack, stroke or death in type 2 diabetes. 9 November 2026 (updated 12 November). pharmaceutical-journal.com
- American Heart Association. GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med (Scientific Sessions 2026 abstract; preliminary). November 2026. newsroom.heart.org
- Eli Lilly and Company. Lilly’s triple agonist retatrutide successful in two additional phase 3 obesity trials. Press release, 23 July 2026 (states planned US submission in Q1 2027). biospace.com
Frequently Asked Questions
What did the November 2026 Italian GLP-1 discontinuation study report?
A retrospective cohort of more than 80,000 people with type 2 diabetes, drawn from roughly 300 Italian diabetes clinics and published in The Lancet Regional Health – Europe on 9 November 2026, reported higher rates of cardiovascular events or death among people who stopped GLP-1 therapy than among those who continued. Press reports cite about 4 versus 2 events per 100 person-years.
Does the study prove that stopping GLP-1 drugs causes cardiovascular events?
No. It is observational. Independent experts quoted in coverage noted that adherence, side effects, socioeconomic circumstances and deteriorating health can all influence both stopping treatment and later outcomes, so the association may be partly or wholly explained by factors the analysis cannot fully capture.
Why do discontinuation studies suffer from bias?
People rarely stop a medicine at random. Illness, adverse effects, cost or frailty can prompt discontinuation and also raise event risk (confounding by indication and reverse causation), and the way follow-up time is assigned can create immortal-time bias. Randomised trials of planned discontinuation are limited.
Does this study involve retatrutide?
No. The cohort concerns licensed GLP-1 receptor agonist medicines used in routine diabetes care. Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist with no approved label anywhere, and it was not part of this dataset.
Is Velox Peptides' retatrutide a medicine?
No. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent for qualified laboratory use. It is not a medicine, is not approved by any regulator, and is not for human or veterinary use.